Boehringer posts flat earnings on stagnant Pradaxa sales

April 22, 2015 8:30 AM

15 0

FRANKFURT, April 22 (Reuters) - Boehringer Ingelheim, Germany's second-largest drugmaker, posted 5.3 percent lower sales and flat operating profit for 2014, hurt by healthcare budget cuts in the United States and stagnant sales of stroke prevention pill Pradaxa.

Full-year operating profit came in at 2.1 billion euros ($2.3 billion), on 13.3 billion euros in sales, the unlisted family-owned group said on Wednesday.

Also read: BMW says spending to rise on autonomous, electric technology

Read more

To category page